IM Cannabis raises $1.31 million in registered direct offering

IM Cannabis Corp., a medical cannabis company operating in Israel and Germany, has raised $1.31 million in a registered direct offering. The securities purchase agreement involved 655,000 common shares priced at $2.00 per share. The gross proceeds are expected to be approximately $1.31 million before expenses. Closing is anticipated on Thursday, pending customary conditions.

The company intends to utilize the net proceeds for working capital and general corporate purposes, which could involve exploring additional business opportunities. The offering is part of an effective shelf registration statement on Form F-3 (File No. 333-288346) declared effective by the Securities and Exchange Commission on July 9, 2025.

IM Cannabis noted that one or more purchasers might be related parties to the company, as defined by Multilateral Instrument 61-101. The board of directors and at least two-thirds of independent directors deemed the company to be in serious financial difficulty, and the offering aims to enhance the company's financial position under reasonable terms. IM Cannabis will retain its Israeli operations while the German ones will be sold.